基于 IFNγ 评分的 III 期黑色素瘤新辅助免疫治疗。

IFNγ score-based neoadjuvant immunotherapy for stage III melanoma.

机构信息

Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Sciences , Kanagawa, Japan.

Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.

出版信息

J Exp Med. 2023 May 1;220(5). doi: 10.1084/jem.20230160. Epub 2023 Mar 15.

DOI:10.1084/jem.20230160

PMID:36920330

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10035434/

Abstract

In this issue of JEM, Reijers et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.

摘要

在本期《实验医学杂志》中，Reijers 等人（2023. J. Exp. Med. https://doi.org/10.1084/jem.20221952）表明，治疗前后 IFNγ 相关基因表达评分是选择 III 期黑色素瘤新辅助免疫治疗的有前途的标志物。